Cargando…

miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma

A number of studies suggest an association between miRNAs and diffuse large B-cell lymphoma (DLBCL). The present study aimed to investigate the prognostic value of microRNA (miR-150) in primary gastrointestinal (PGI)-DLBCL, by assessing the association between miR-150 expression and clinicopathologi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xinyuan, Kan, Yutian, Chen, Leiyuan, Ge, Peng, Ding, Tingting, Zhai, Qiongli, Yu, Yong, Wang, Xiaofang, Zhao, Zhigang, Yang, Hongliang, Liu, Xianming, Li, Lanfang, Qiu, Lihua, Qian, Zhengzi, Zhang, Huilai, Wang, Yafei, Zhao, Haifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115130/ https://www.ncbi.nlm.nih.gov/pubmed/32269622 http://dx.doi.org/10.3892/ol.2020.11452

Ejemplares similares

Overexpression of microRNA-130a predicts adverse prognosis of primary gastrointestinal diffuse large B-cell lymphoma
por: Chen, Leiyuan, et al.
Publicado: (2020)

Genetic polymorphism and transcriptional regulation of CREBBP gene in patient with diffuse large B-cell lymphoma
por: Zhao, Haifeng, et al.
Publicado: (2019)

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma
por: Zhang, Tingting, et al.
Publicado: (2020)

Corrigendum to “Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma”
por: Zhang, Tingting, et al.
Publicado: (2021)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma
por: Wu, Zizheng, et al.
Publicado: (2021)

A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

SIRT1 rs3758391 polymorphism and risk of diffuse large B cell lymphoma in a Chinese population
por: Kan, Yutian, et al.
Publicado: (2018)

Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
por: Qu, Zhenjie, et al.
Publicado: (2022)

PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B‐cell lymphoma
por: Zhang, Huilai, et al.
Publicado: (2022)

Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer
por: Zhao, Peiqi, et al.
Publicado: (2021)

Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients
por: Fei, Yue, et al.
Publicado: (2020)

Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy
por: Zhao, Peiqi, et al.
Publicado: (2022)

Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China
por: Gao, Fenghua, et al.
Publicado: (2022)

A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells
por: Dong, Ling, et al.
Publicado: (2016)

Pan-Cancer Analysis Reveals Genomic and Clinical Characteristics of TRPV Channel-Related Genes
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment
por: Zhang, Tingting, et al.
Publicado: (2022)

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T‐cell lymphomas
por: Zhang, Xuhan, et al.
Publicado: (2019)

Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma
por: Qian, Zhengzi, et al.
Publicado: (2015)

A retrospective analysis of EBV‐DNA status with the prognosis of lymphoma
por: Qiu, Lihua, et al.
Publicado: (2022)

A Phase I Trial to Evaluate the Multiple-Dose Safety and Antitumor Activity of Ursolic Acid Liposomes in Subjects with Advanced Solid Tumors
por: Qian, Zhengzi, et al.
Publicado: (2015)

Multiplex ligation-dependent probe amplification identifies copy number changes in normal and undetectable karyotype MDS patients
por: Ma, Jing, et al.
Publicado: (2021)

An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy
por: Lu, Yaxiao, et al.
Publicado: (2021)

Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma
por: Li, Yang, et al.
Publicado: (2021)

miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma
por: Fan, Qian, et al.
Publicado: (2016)

SET-NUP214 Fusion Gene Involved Early T-Cell Precursor Acute Lymphoblastic Leukemia in Adult with B Marker Expression
por: Xu, Xiaoying, et al.
Publicado: (2021)

Comorbidity as an independent prognostic factor in elderly patients with peripheral T-cell lymphoma
por: Zhao, Haifeng, et al.
Publicado: (2016)

A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma
por: Xu, Hong, et al.
Publicado: (2022)

Development of The Chinese Version of Ultra-Low Vision Visual Functioning Questionnaire-150
por: Cong, Jing, et al.
Publicado: (2023)

Immunophenotypic Landscape and Prognosis-Related mRNA Signature in Diffuse Large B Cell Lymphoma
por: Jiang, Yanan, et al.
Publicado: (2022)

Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
por: Tian, Chen, et al.
Publicado: (2021)

Characteristics and outcomes of non-Hodgkin’s lymphoma patients with leptomeningeal metastases
por: Meng, Xiangrui, et al.
Publicado: (2018)

Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors
por: Cao, Yang, et al.
Publicado: (2016)

Gastrointestinal Mucormycosis of the Jejunum in an Immunocompetent Patient: A Case Report
por: Sun, Mengqing, et al.
Publicado: (2017)

Canada 150
por: D’Eon, Marcel
Publicado: (2017)

Correlation Between Uptake of (18)F-FDG During PET/CT and Ki-67 Expression in Patients Newly Diagnosed With Multiple Myeloma Having Extramedullary Involvement
por: Li, Qian, et al.
Publicado: (2019)

Integrated analysis of genome-wide gene expression and DNA methylation microarray of diffuse large B-cell lymphoma with TET mutations
por: Liu, Pengfei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sjvkp7cumm9vrvrmte5mjcj7h5